Ascendis Pharma ( (ASND) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ascendis Pharma’s stock is on the rise following a price target increase by Stifel, even as the company navigates an FDA delay for its TransCon CNP approval. The boost comes on the heels of a robust earnings report showcasing significant revenue growth, which has bolstered the company’s market standing. Analysts continue to endorse a strong buy rating for Ascendis Pharma, highlighting its promising long-term outlook.
More about Ascendis Pharma
YTD Price Performance: 52.29%
Average Trading Volume: 528,007
Technical Sentiment Signal: Buy
Current Market Cap: $12.3B
For further insights into ASND stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.